ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Durham, NC, USA:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

Durham, North Carolina, United States and 125 other locations

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Chapel Hill, North Carolina, United States and 164 other locations

to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...

Enrolling
Relapsed Adult AML
Leukemia, Myeloid, Acute
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Durham, North Carolina, United States and 33 other locations

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...

Active, not recruiting
AML
Acute Myelogenous Leukemia
Drug: Iomab-B
Drug: Conventional Care

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Chapel Hill, North Carolina, United States and 23 other locations

Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute...

Active, not recruiting
AML, Adult
Acute Myeloid Leukemia
Drug: venetoclax
Drug: azacitidine

Phase 1, Phase 2

ALX Oncology

Durham, North Carolina, United States and 4 other locations

to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy.Participants will...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Pevonedistat
Drug: Venetoclax

Phase 2

Takeda
Takeda

Chapel Hill, North Carolina, United States of America and 56 other locations

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...

Active, not recruiting
Acute Myeloid Leukemia
Drug: MBG453
Drug: Venetoclax

Phase 2

Novartis
Novartis

Durham, North Carolina, United States and 27 other locations

Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using mul...

Enrolling
Chronic Myelocytic Leukemia
Acute Myeloid Leukemia
Drug: Azacitidine
Drug: ASTX030 (cedazuridine + azacitidine)

Phase 2, Phase 3

Taiho Pharma
Taiho Pharma

Durham, North Carolina, United States and 21 other locations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Chronic Myelomonocytic Leukemia (CMML)
Drug: Azacitidine
Drug: LY3410738

Phase 1

Lilly
Lilly

Chapel Hill, North Carolina, United States of America and 36 other locations

with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML...

Enrolling
Relapsed/Refractory AML
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Azacitidine

Phase 1, Phase 2

Faron Pharmaceuticals

Chapel Hill, North Carolina, United States of America and 8 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems